Biogen Buys Apellis for $5.6B to Expand Kidney Drugs
Bloomberg’s Michelle Davis joins Dani Burger on “Bloomberg Deals.” Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, expanding…
Tag: Apellis
Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise
Biogen Inc. has agreed to acquire Apellis Pharmaceuticals Inc. for $5.6 billion, expanding its treatments in immunology and rare diseases…